Decolonization before chemo / transplant
Patients heading into intensive chemotherapy or allogeneic hematopoietic stem cell transplant (HSCT) routinely undergo profound neutropenia and gut-barrier breakdown, so the gut becomes the launchpad for life-threatening bloodstream infections. Domination of the intestinal microbiota by multidrug-resistant Gram-negative E. coli (notably ESBL/carbapenemase ST131 clones) and by Enterococcus (VRE and cytolytic E. faecalis) directly precedes bacteremia and, for Enterococcus, worsens acute graft-versus-host disease. Antibiotic decolonization fails because it cannot durably clear these organisms and further wrecks the protective microbiome. Lytic bacteriophages are attractive here because they kill target strains with surgical specificity, self-amplify on their host, penetrate biofilms, and spare the commensal flora that confers colonization resistance — exactly the profile needed to shrink a pathogen reservoir without collateral dysbiosis before a transplant.
How phages act here
Mechanism
Phages bind strain-specific surface receptors (LPS O-antigen, capsule, or pili on E. coli; cell-wall and EPS structures on Enterococcus), so a curated cocktail can be matched to a carrier's resident clone and broaden host range while raising the genetic barrier to escape mutants. Against gut E. coli ST131 and Enterococcus, cocktails reduce luminal bacterial load by orders of magnitude in vitro and transiently in vivo, but phage-resistant mutants and rapid GI transit (phages get diluted/inactivated during passage) limit durability — which is why synergy strategies dominate the field. Demonstrated combinations include phage plus a microcin-producing engineered E. coli Nissle probiotic (striking synergy against ST131 gut colonization) and phage plus antibiotics (phage-antibiotic synergy, e.g., daptomycin/ampicillin against enterococcal biofilm). For biofilm-forming, antibiotic-tolerant cytolytic E. faecalis, a phage-derived lytic enzyme (endolysin) degrades the biofilm matrix with narrow-spectrum specificity (lysing E. faecalis but not E. faecium), and engineered/depolymerase and CRISPR-Cas3 approaches are emerging to make the kill sequence-programmable.
Where it stands
Current evidence
As of 2026 the evidence is preclinical and proof-of-concept, not yet validated by a controlled decolonization trial in pre-transplant patients. For gut E. coli, the Endimiani group (Bern) showed the commercial INTESTI cocktail crashed CTX-M-15 ST131 E. coli in a human-feces continuous-culture model, though a phage-resistant mutant emerged in one of two donor microbiotas (2020); a Minneapolis VA/University of Minnesota team then showed phage alone was only weakly/transiently effective against ST131 gut colonization in mice but achieved ~3.3-log reduction when co-administered with a microcin-producing probiotic (2022). For Enterococcus, a 2024 Nature paper (Uematsu group, Osaka/Tokyo) directly tied cytolytic E. faecalis gut domination to acute GVHD after allo-HCT and showed an E. faecalis-specific phage-derived enzyme decolonized the gut and improved survival in humanized gnotobiotic mice, while a 2024 Nature Communications study demonstrated a five-phage cocktail lowers VRE fecal burden in mice but flagged anti-phage immunity as an efficacy barrier. Clinically, registered gut-decolonization trials for CRE/VRE are accumulating, but the active ones (e.g., the 2026 BM111 trial, NCT07525089) test microbial-consortium/FMT-type products rather than phage cocktails; named phage-decolonization programs remain mostly at the company/early-clinical and compassionate-use stage.
Evidence confidence: low
The data
Key studies & trials
- Fujimoto K, Hayashi T, Yamamoto M, et al. An enterococcal phage-derived enzyme suppresses graft-versus-host disease. Nature. 2024;632(8023):174-181. ↗
- Bernasconi OJ, Campos-Madueno EI, Donà V, Perreten V, Carattoli A, Endimiani A. Investigating the use of bacteriophages as a new decolonization strategy for intestinal carriage of CTX-M-15-producing ST131 Escherichia coli: An in vitro continuous culture system model. J Glob Antimicrob Resist. 2020;22:664-671. ↗
- Porter SB, Johnston BD, Kisiela D, Clabots C, Sokurenko EV, Johnson JR. Bacteriophage Cocktail and Microcin-Producing Probiotic Nissle-1917 Protect Mice Against Gut Colonization With Multidrug-Resistant Escherichia coli Sequence Type 131. Front Microbiol. 2022;13:887799. ↗
- Cheng M, et al. Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin-Resistant Enterococcus in a murine model. Nat Commun. 2024;15:3104. doi:10.1038/s41467-024-47192-w. ↗
Who is working on it
Programs & centers
The possibility
The near-term vision is a 'phage prep' built into the pre-transplant checklist: sequence a candidate's gut isolates, assemble a personalized cocktail (likely paired with a probiotic or short antibiotic course to blunt resistance), and knock the resistant E. coli or Enterococcus reservoir down to a safe threshold before conditioning begins — shrinking the pool from which post-transplant bacteremia and Enterococcus-driven GVHD arise. Engineered phages, CRISPR-Cas3 sequence-targeting, and narrow-spectrum endolysins that dissolve enterococcal biofilms without touching protective commensals could make this both precise and microbiome-sparing, turning decolonization into a routine, low-collateral procedure. If the anti-phage immunity and durability hurdles are solved through cocktail rotation and synergy, phage-based decolonization could become one of the first mainstream clinical uses of phage therapy in immunocompromised oncology patients.